Clicky

vTv Therapeutics Inc.(VTVT)

Description: vTv Therapeutics Inc., a biopharmaceutical company, engages in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease includes azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. The company's type 2 diabetes drug candidates comprise TTP399, an orally administered, liver-selective glucokinase activator, which is in a Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor that has completed Phase I clinical trials. It is also developing HPP593, a functionally selective peroxisome proliferator-activated receptor delta agonist for the prevention of muscle weakness associated with prolonged mechanical ventilation and critical injury that has completed Phase Ib clinical trials; HPP737, an orally administered phosphodiesterase-4 inhibitor for the treatment of chronic obstructive pulmonary disease, psoriasis, and other inflammatory diseases, which has completed Phase Ib clinical trials; and HPP971, a Bach1 inhibitor, for the treatment of inflammation, autoimmune diseases, and diseases associated with oxidative stress, which is in Phase 1 clinical trials. The company has a license and research agreement with Calithera Biosciences, Inc. to research, develop, and commercialize its hexokinase II inhibitors for therapeutics, prophylactic, preventative, or diagnostic use. vTv Therapeutics Inc. was founded in 2015 and is headquartered in High Point, North Carolina.


Keywords: Medicine Biopharmaceutical Disease Diabetes Autoimmune Disease Inflammation Alzheimer's Disease Parkinson's Disease Psoriasis Inflammatory Diseases Organic Chemistry Chronic Obstructive Pulmonary Disease Pulmonary Disease Treatment Of Alzheimer's Disease Mechanical Ventilation Pyridines Tyrosine Kinase Inhibitors Treatment Of Chronic Obstructive Pulmonary Disease Biotie Therapies Oxidative Stress Phosphodiesterase Treatment Of Inflammation Buparlisib

Home Page: www.vtvtherapeutics.com

VTVT Technical Analysis

3980 Premier Drive
High Point, NC 27265
United States
Phone: 336 841 0300


Officers

Name Title
Mr. Paul J. Sekhri M.Sc., MSc CEO, Pres & Director
Mr. Barry Brown Chief Accounting Officer
Dr. Carmen Valcarce Ph.D. Chief Scientific Officer & Exec. VP
Vanessa McDade Chief Admin. Officer
Mr. David M. Lambert III Sr. VP & Gen. Counsel
Mr. Richard S. Nelson Exec. VP of Corp. Devel. & Director

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 27.6511
IPO Date: 2015-07-30
Fiscal Year End: December
Full Time Employees: 9
Back to stocks